Keyphrases
3′ End Formation
24%
3′ End Processing
24%
ABCC11
96%
Acquired mutations
32%
Activity-dependent Gene Expression
48%
Deep Resequencing
32%
Differentially Methylated Regions
48%
DNA Methyltransferase 3B (DNMT3B)
48%
Downstream Genes
48%
Druggability
24%
Earwax
96%
End-stage Cancer
24%
Endogenous Genes
24%
Eukaryotic Genomes
48%
Functional Coupling
24%
Gene Activity
48%
Gene Body
24%
GRB10
96%
Histone H3 Lysine 27
96%
Human Promoter
96%
Imprinting Center
96%
Intratumor
32%
Late-stage Cancer
96%
Low-frequency mutation
32%
Mammalian Proteins
48%
Molecular Heterogeneity
96%
Molecular Tumor Board
72%
MRNA 3′ End Processing
96%
Multifocal Disease
96%
Normal Urothelium
64%
Polyadenylation Sites
48%
Polycomb Group (PcG) Proteins
41%
Promoter Binding
48%
Readthrough
24%
Regulatory Potential
48%
RNA Exosome
48%
RNA Maturation
24%
RNA Polymerase II (RNAPII)
96%
Small nuclear Ribonucleoprotein (snRNP)
96%
SNRPN
96%
TFIIB
48%
Tiling Microarray
48%
Transcript Expression
96%
Transcription Cycle
24%
Transcription Initiation
96%
Transcription Unit
24%
Transcriptome Map
48%
Tumorigenic Transformation
32%
UV Analysis
48%
UV Treatment
48%
Biochemistry, Genetics and Molecular Biology
Allele
96%
Angelman Syndrome
72%
Brain Cell Culture
9%
Cis Acting Element
24%
DAP (Gene)
10%
Differentially Methylated Regions
72%
DNA Methylation
96%
DNMT3B
10%
Enhancer Region
48%
Exome Sequencing
96%
Exon
24%
Gene Activity
10%
Gene Mutation
96%
Gene Polymorphism
24%
Genotyping
24%
Germ Cell
72%
Germline
48%
Glial Cells
9%
Globin Gene
16%
Haplotype
24%
Histone H3
96%
Intron
48%
Methylation
96%
Mouse
96%
Mutation Rate
96%
Nerve Cell Culture
24%
Polycomb-Group Proteins
28%
Promoter Region
24%
RNA Degradation
24%
RNA Polymerase II
40%
Single Nucleotide Polymorphism
96%
Small Nuclear Ribonucleoprotein Polypeptide N
96%
Somatic Cell
24%
Transcription Termination
16%
Transcriptomics
96%
Medicine and Dentistry
Biological Marker
24%
Bladder Cancer
96%
Cancer Staging
96%
Clinical Trial
48%
Diseases
96%
Exome Sequencing
13%
Gene Mutation
13%
Lung Cancer
24%
Lymph Node Metastasis
13%
Malignant Neoplasm
72%
Molecular Profiling
24%
Mutation Rate
13%
Neoplasm
100%
Personalized Medicine
96%
Prostate Cancer
24%
Recurrent Disease
13%
Targeted Therapy
96%
Transcriptomics
13%
Tumor Biopsy
24%
Tumour Heterogeneity
27%